News for Unity Biotechnology, Inc. (0YC0.L)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Unity Biotechnology (UBX) has been downgraded by H.C. Wainwright from a "Buy" to a "Neutral" rating, with its price target reduced to $2 from $4. This adjustmen

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio) made a significant move by acquiring an additional 414,569 shares of Volcon Inc (VLCN) at a p

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving BTC Digital Ltd (B

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio) executed a significant reduction in its holdings of Flora Growth Corp (FLGC). The firm decrea

UNITY Biotechnology (UBX) has unveiled the complete 36-week findings from their Phase 2b ASPIRE trial, focusing on the intravitreal treatment UBX1325 for patien

UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population

**media[614539]**

Empery Asset Management, LP (Trades, Portfolio), a prominent investment firm, recently made a significant adjustment to its holdings in Knightscope Inc. On Marc

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio) executed a transaction involving Sobr Safe Inc (SOBR), reducing its holdings by 2,217 shares.

On March 31, 2025, Empery Asset Management, LP (Trades, Portfolio) made a significant move by reducing its holdings in Bullfrog AI Holdings Inc by 46.82%. This

Empery Asset Management, LP (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Sidus Space Inc. On March 31

UNITY Biotechnology, Inc. (UBX) has announced promising findings from a study published in the journal NEJM Evidence regarding its UBX1325 treatment for patient

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (”œUNITY”) [ UBX], a biotechnology company developing therapeutic

Unity Biotechnology (UBX) reported a decrease in its cash, cash equivalents, and marketable securities, which totaled $16.9 million as of March 31. This is a de

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 350 points on Monday. The Dow traded up 1.35% to 42,551.10 while ...

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. Following the market opening Monday, the Dow traded up...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inf

SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (”œUNITY”) [ UBX], a biotechnology company developing therapeutic